Budget Impact Analysis of the Introduction of Injectable Prolonged-Release Buprenorphine on Opioid Use Disorder Care Resource Requirements

References

• Murray CJL, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197–2223. doi:10.1016/S0140-6736(12)61689-4
   PubMed Web of Science ®Google Scholar
• Dematteis M, Auriacombe M, D’Agnone O, et al. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;18(18):1987–1989. doi:10.1080/14656566.2017.1409722
   PubMed Web of Science ®Google Scholar
• Callaham S, LoSasso A, Olson B. Income generation in recovering heroin users: a comparative analysis of legal and illegal earning. J Offender Rehabil. 2015;54(5):338–349. doi:10.1080/10509674.2015.1043479
   Google Scholar
• National Alliance to End Homelessness. Opioid abuse and homelessness. National Alliance to End Homelessness; 2016. Available from: https://endhomelessness.org/resource/opioid-abuse-and-homelessness/.
   Google Scholar
• Daley DC. Family and social aspects of substance use disorders and treatment. J Food Drug Anal. 2013;21(4):S73–S76. doi:10.1016/j.jfda.2013.09.038
   PubMed Web of Science ®Google Scholar
• Nielsen S, Degenhardt L, Larance B, Gowing L, Kehler C, Lintzeris N. Opioid agonist treatment for pharmaceutical opioid dependent people (Protocol). Cochrane Database Syst Rev. 2016. doi:10.1002/14651858.CD011117
   Web of Science ®Google Scholar
• Stöver H. Barriers to opioid substitution treatment access, entry and retention: survey of opioid users, patients in treatment, and treating and non-treating physicians. Eur Addict Res. 2010;17(1):44–54. doi:10.1159/000320576
   Web of Science ®Google Scholar
• Anstice S, Strike CJ, Brands B. Supervised methadone consumption: client issues and stigma. Subst Use Misuse. 2009;44(6):794–808. doi:10.1080/10826080802483936
   PubMed Web of Science ®Google Scholar
• Vigilant LG. The stigma paradox in methadone maintenance: naïve and positive consequences of a “treatment punishment” approach to opiate addiction. Sage. 2004;28(4):403–418.
   Google Scholar
• European Medicines Agency. Buvidal Buprenorphine, summary of opinion (initial authorisation). 2018.
   Google Scholar
• European Medicines Agency. Buvidal - summary of product characteristics; 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/buvidal-epar-product-information_en.pdf.
   Google Scholar
• European Medicines Agency. Assessment Report - Buvidal - International Non-Proprietary Name: buprenorphine; 2018. Available from: https://www.ema.europa.eu/en/documents/assessment-report/buvidal-epar-public-assessment-report_en.pdf.
   Google Scholar
• Albayaty M, Linden M, Olsson H, Johnsson M, Strandgården K, Tiberg F. Pharmacokinetic evaluation of once-weekly and once-monthly buprenorphine subcutaneous injection depots (CAM2038) versus intravenous and sublingual buprenorphine in healthy volunteers under naltrexone blockade: an open-label phase 1 study. Adv Ther. 2017;34(2):560–575. doi:10.1007/s12325-016-0472-9
   PubMed Web of Science ®Google Scholar
• Walsh SL, Comer SD, Lofwall MR, et al. Effect of buprenorphine weekly depot (CAM2038) and hydromorphone blockade in individuals with opioid use disorder: a randomized clinical trial. JAMA Psychiatry. 2017;74(9):894–902. doi:10.1001/jamapsychiatry.2017.1874
   PubMed Web of Science ®Google Scholar
• Haasen C, Linden M, Tiberg F. Pharmacokinetics and pharmacodynamics of a buprenorphine subcutaneous depot formulation (CAM2038) for once-weekly dosing in patients with opioid use disorder. J Subst Abuse Treat. 2017;78:22–29. doi:10.1016/j.jsat.2017.04.008
   PubMed Web of Science ®Google Scholar
• Lofwall MR, Walsh SL, Nunes EV, et al. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder a randomized clinical trial. JAMA Intern Med. 2018;178(6):764–773. doi:10.1001/jamainternmed.2018.1052
   PubMed Web of Science ®Google Scholar
• Institute for Clinical and Economic Review. Extended-release opioid agonists and antagonists for Medication- Assisted Treatment (MAT) of opioid use disorder: effectiveness and value. 2018.
   Google Scholar
• Frost M, Bailey GL, Lintzeris N, et al. Long-term safety of a weekly and monthly subcutaneous buprenorphine depot (CAM2038) in the treatment of adult outpatients with opioid use disorder. Addiction. 2019;114(8):1416–1426. doi:10.1111/add.14636
   Web of Science ®Google Scholar
• Gilman M, Li L, Hudson K, et al. Current and future options for opioid use disorder: a survey assessing real-world opinion of service users on novel therapies including depot formulations of buprenorphine. Patient Prefer Adherence. 2018;12:2123–2129. doi:10.2147/PPA.S180641
   PubMed Web of Science ®Google Scholar
• England Public Health. United Kingdom drug situation: focal point annual report 2017. 2017. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/713101/Focal_Point_Annual_Report.pdf.
   Google Scholar
• England Public Health. Alcohol and drug treatment for adults: statistics summary 2017 to 2018. 2018.
   Google Scholar
• National Treatment Agency for Substance Misuse. JSNA support pack for commissioners of recovery in communities 2013 JSNA support pack for commissioners. 2013;(April).
   Google Scholar
• National Audit Office. Public Health England’s Grant to Local Authorities; 2014.
   Google Scholar
• Connock M, Juarez-Garcia A, Jowett S, et al. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technol Assess. 2007;11(9):1–37.
   PubMed Web of Science ®Google Scholar
• Gibbons C, Jensen R Modelling the budgetary impact of treating opioid dependence in the English municipal setting. 2018.
   Google Scholar
• Kenworthy J, Yi Y, Wright A, Brown J, Maria Madrigal A, Dunlop WCN. Use of opioid substitution therapies in the treatment of opioid use disorder: results of a UK cost-effectiveness modelling study. J Med Econ. 2017;20(7):740–748. doi:10.1080/13696998.2017.1325744
   PubMed Web of Science ®Google Scholar
• NHS. Amendments to the drug tariff April 2019; April 2019. Available from: https://www.nhsbsa.nhs.uk/sites/default/files/2019-03/. Drug Tariff April 2019.pdf.
   Google Scholar
• Department of Health (England). Clinical Guidelines on Drug Misuse and Dependence Update 2017. London: Independent Expert Working Group; 2017.
   Google Scholar
• NHS. Drug tariff 2018. 2018.
   Google Scholar
• PSNC. Changes to oral liquid methadone fee arrangements FAQs – March 2013. 2013.
   Google Scholar
• Clinical Guidelines on Drug Misuse and Dependence Update 2017 Independent Expert Working Group. Drug Misuse and Dependence: UK Guidelines on Clinical Management. London: Global and Public Health/Population Health/Healthy Behaviours/25460; 2017.
   Google Scholar
• Pinto H, Maskrey V, Swift L, Rumball D, Wagle A, Holland R. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. J Subst Abuse Treat. 2010;39(4):340–352. doi:10.1016/j.jsat.2010.07.009
   PubMed Web of Science ®Google Scholar
• Trial record. Clinical trial of CAM2038, long-acting subcutaneous buprenorphine injections for treatment of patients with opioid dependence. Available from: https://clinicaltrials.gov/ct2/show/NCT02651584?term=NCT02651584&rank=1. Accessed May 24, 2019.
   Google Scholar
• Tiberg F, Jensen R, Sanjurjo V, Carter J. Substitution therapy with flexible-dose depot buprenorphine injection to treat opioid use disorder in the United Kingdom: a pharmacoeconomic assessment. Value Health. 2017;20(9):A711. doi:10.1016/j.jval.2017.08.1880
   Web of Science ®Google Scholar
• Jensen R, Carter J, Tiberg F, Sanjurjo V. Flexible-dose depot buprenorphine injection for opioid substitution treatment in heroin-addicted adults: a Swedish pharmacoeconomic perspective. Value Health. 2017;20(9):A711. doi:10.1016/j.jval.2017.08.1879
   Web of Science ®Google Scholar
• Burkinshaw P, Knight J, Anders P, et al. An Evidence Review of the Outcomes That Can Be Expected of Drug Misuse Treatment in England. 2017. London. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/586111/PHE_Evidence_review_of_drug_treatment_outcomes.pdf
   Google Scholar
• National Institute for Health and Care Excellence. Evidence review opioid dependence: buprenorphine prolonged- release injection (Buvidal); 2019. Available from: https://www.nice.org.uk/advice/es19/evidence/evidence-review-pdf-6666819661.
   Google Scholar
• Methadone dispensing (FP10 and FP10MDA).
   Google Scholar
• PSNC. Pharmaceutical services negotiating committee - fees and allowances; 2018. https://psnc.org.uk/dispensing-supply/endorsement/fees-allowances/. Accessed December 20, 2018..
   Google Scholar
• National Institute for Health and Care Excellence (NICE). Costing statement: needle and syringe programmes; 2014. Available from: https://www.nice.org.uk/guidance/ph52/resources/ph52-needle-and-syringe-programmes-costing-statement2.
   Google Scholar
• Langham S, Wright A, Kenworthy J, Grieve R, Dunlop WCN. Cost-effectiveness of take-home naloxone for the prevention of overdose fatalities among heroin users in the United Kingdom. Value Health. 2018;21(4):407–415. doi:10.1016/j.jval.2017.07.014
   PubMed Web of Science ®Google Scholar
• Curtis L. Unit costs of health & social care 2017. Pers Social Serv Res Unit. 2017. doi:10.1016/j.cemconcomp.2014.07.014
   Google Scholar